Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its position in Amgen Inc. (NASDAQ:AMGN – Get Rating) by 2.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 95,032 shares of the medical research company’s stock after acquiring an additional 2,205 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Amgen were worth $22,981,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Cetera Advisors LLC grew its stake in shares of Amgen by 19.6% during the third quarter. Cetera Advisors LLC now owns 20,130 shares of the medical research company’s stock valued at $4,281,000 after buying an additional 3,303 shares during the last quarter. Easterly Investment Partners LLC purchased a new stake in shares of Amgen during the third quarter worth about $2,152,000. Schonfeld Strategic Advisors LLC purchased a new stake in Amgen in the third quarter worth about $309,000. Summit Trail Advisors LLC lifted its holdings in Amgen by 23.4% in the third quarter. Summit Trail Advisors LLC now owns 1,720 shares of the medical research company’s stock worth $366,000 after buying an additional 326 shares during the period. Finally, Studio Investment Management LLC purchased a new stake in Amgen in the third quarter worth about $3,539,000. 79.01% of the stock is currently owned by institutional investors and hedge funds.
Shares of AMGN traded up $2.26 during trading hours on Thursday, reaching $242.40. 36,830 shares of the stock traded hands, compared to its average volume of 3,428,608. The company has a market cap of $129.49 billion, a P/E ratio of 23.73, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. Amgen Inc. has a 52-week low of $198.64 and a 52-week high of $258.45. The company has a current ratio of 1.44, a quick ratio of 1.09 and a debt-to-equity ratio of 39.31. The company’s 50-day moving average price is $244.62 and its two-hundred day moving average price is $234.69.
In other Amgen news, Director R Sanders Williams sold 600 shares of the business’s stock in a transaction dated Monday, May 23rd. The shares were sold at an average price of $250.00, for a total value of $150,000.00. Following the completion of the sale, the director now directly owns 5,501 shares of the company’s stock, valued at approximately $1,375,250. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Jonathan P. Graham sold 13,500 shares of the business’s stock in a transaction dated Tuesday, May 10th. The shares were sold at an average price of $241.81, for a total transaction of $3,264,435.00. Following the completion of the sale, the executive vice president now directly owns 37,333 shares of the company’s stock, valued at $9,027,492.73. The disclosure for this sale can be found here. Corporate insiders own 0.46% of the company’s stock.
Several analysts have commented on the stock. BMO Capital Markets lowered their price objective on shares of Amgen from $263.00 to $243.00 in a report on Thursday, April 28th. SVB Leerink started coverage on shares of Amgen in a research note on Monday, May 23rd. They set a “market perform” rating and a $256.00 target price for the company. Morgan Stanley decreased their target price on shares of Amgen from $238.00 to $237.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 12th. TheStreet downgraded shares of Amgen from a “b+” rating to a “c+” rating in a research report on Wednesday, April 27th. Finally, Oppenheimer raised their price target on shares of Amgen from $285.00 to $290.00 and gave the company an “outperform” rating in a research report on Wednesday, June 1st. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Amgen presently has a consensus rating of “Hold” and an average target price of $242.57.
Amgen Company Profile (Get Rating)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
- Get a free copy of the StockNews.com research report on Amgen (AMGN)
- It’s A Comfortable Time To Buy Steelcase
- Worthington’s Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
- NXP Semiconductors: Strong Earnings & New Microcontrollers for Electric Vehicles
- Lithium Stocks Are Offering Unprecedented Opportunity To Investors
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.